Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Bevacizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
NCT04723004Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Oct 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04723004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723004.